Lymphoid blastic crisis of chronic myelogenous leukemia
Chronic myelogenous leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP) patient must have failed or be intolerant to imatinib mesylate
Diagnosis of Burkitt's leukemia/lymphoma according to WHO classification or chronic myelogenous leukemia lymphoid blast crisis
Chronic myelogenous leukemia in chronic or accelerated phase, or chronic myelogenous leukemia (CML) blast crisis in morphological remission (< % blasts): chronic phase patients must have failed at least two tyrosine kinase inhibitors been intolerant to all available tyrosine kinase inhibitors (TKIs) or have TI mutation
Chronic myelogenous leukemia excluding refractory blast crisis: To be eligible in first chronic phase (CP) patient must have failed or be intolerant to imatinib mesylate
Newly diagnosed or relapsed chronic myelogenous leukemia (CML) in lymphoid blast crisis
BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
Chronic myelogenous leukemia: All types, except refractory blast crisis; chronic phase patients must have failed or been intolerant to Gleevec or other tyrosine kinase inhibitors
Chronic myelogenous leukemia: All types, except refractory blast crisis; chronic phase patients must have failed or been intolerant to Gleevec or other tyrosine kinase inhibitors; at time of transplant, patients must have < % blasts in an evaluable marrow (> % of normal cellularity for age) by morphology within the bone marrow
Chronic myelogenous leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP) patient must have failed or be intolerant to imatinib mesylate
Chronic myelogenous leukemia: all types except refractory blast crisis; chronic phase patients must have failed or been intolerant to Gleevec
Chronic myelogenous leukemia (CML) in refractory blast crisis
Chronic myelogenous leukemia excluding refractory blast crisis: to be eligible in first chronic phase (CP) patient must have failed or be intolerant to one or more tyrosine kinase inhibitors
Diagnosis of chronic myelogenous leukemia in blast crisis;
Diagnosis of mature B-cell ALL (Burkitts leukemia) according to World Health Organization (WHO) classification, or lymphoid blast crisis of chronic myelogenous leukemia (CML)
Patients must have an initial diagnosis of AML, biphenotypic acute leukemia, or APL or chronic myelogenous leukemia (CML) in blast crisis
Chronic myelogenous leukemia (accelerated, blast or second chronic phase)
Chronic myelogenous leukemia all types except blast crisis (note treated blast crisis in chronic phase is eligible)
Chronic myelogenous leukemia (CML) in refractory blast crisis
Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
Diagnosis of Burkitt's Leukemia, or lymphoid blast crisis of chronic myelogenous leukemia (CML)
Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
Diagnosis of Burkitt's leukemia/lymphoma according to WHO classification or chronic myelogenous leukemia lymphoid blast crisis
Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
Patients with chronic myelogenous leukemia (CML) in myeloid blast crisis are eligible if their disease has failed to respond, and/or they are intolerant, to the available tyrosine kinase inhibitors (TKIs)
Chronic myelogenous leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP) patient must have failed or be intolerant to tyrosine kinase inhibitor therapy
Burkitt's lymphoma/leukemia or chronic myelogenous leukemia lymphoid blast crisis (p BCR-ABL+)
Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
Refractory/relapsing blast crisis of chronic myelogenous leukemia (CML)
Diagnosis of chronic myelogenous leukemia in blast crisis
Chronic myelogenous leukemia: all types except refractory blast crisis; chronic phase patients must have failed or been intolerant to at least one tyrosine-kinase inhibitor
Chronic myelogenous leukemia: all types except refractory blast crisis; chronic phase patients must have failed at least two different tyrosine-kinase inhibitors (TKIs), or been intolerant to all available TKIs or have TI mutation
Chronic myelogenous leukemia (CML) in blast crisis
